A Randomised, Double-blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Topically Applied DGLA Cream in Patients with Mild to Moderate Atopic Dermatitis - Safety and Efficacy Study of DGLA Cream in Patients with Atopic Dermatitis

Dignity Sciences Limited0 sites200 target enrollmentDecember 21, 2012

Overview

No summary available.

Registry

who.int

Start Date

December 21, 2012

End Date

TBD

Last Updated

9 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

Dignity Sciences Limited

•1\.Clinically confirmed diagnosis of active atopic dermatitis according to Hanifin and Rajka criteria.
•2\.Patients with mild to moderate atopic dermatitis at screening; Rajka\-Langeland score 3\-7\.5\.
•3\. Patients with mild to moderate atopic dermatitis covering 2\-50% of the body surface area
•4\.Male or female patients aged 18 years and older on the day of signing the informed consent form (ICF).
•5\.Patients in general good health as confirmed by a physical examination and by medical history.
•6\.Patients who are able and willing to give signed informed consent (ICF).
•7\.Patient’s body mass index (BMI) is between 18 and 30 kg/m2 inclusive.
•8\.Female patients of child bearing potential, and female partners of male patients, must use adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgical sterile) for the duration of the study; or agree to sexual abstinence for the duration of the study.
•9\.Patients who are able and willing to stop treatment for atopic dermatitis for the washout period (except emollients).
•Are the trial subjects under 18? no

•1\.Females with positive pregnancy test at screening (Visit 1\) or start of treatment/baseline (Visit 2\) or lactating women.
•2\.Patients who have received phototherapy (UVA, UVB) within 4 weeks of screening (Visit 1\).
•3\.Patients with Netherton’s Syndrome.
•4\.Patients with clinically significant impairment of renal or hepatic function.
•5\.Patients with other skin conditions that might interfere with atopic dermatitis diagnosis and/or evaluation (such as psoriasis, viral, bacterial and fungal skin infections).
•6\.Patients with a history of hypersensitivity to any substance in the IMP.
•7\.Patients with severe atopic dermatitis; Rajka\-Langeland score 8\-9\.
•8\.Patients with a history of clinically relevant ECG abnormalities
•9\.Patients treated with any experimental drug within 30 days prior to start of treatment/baseline visit (Visit 2\).
•10\.Patients who have used any of the medications and therapeutic regimens excluded from the study within 14 days prior to baseline/day 0 visit (Visit 2\).